S 60
Latest Information Update: 20 Jun 2001
At a glance
- Originator Unknown
- Developer Kyorin Pharmaceutical
- Class Cytostatic antibiotics
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Jun 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)